Skip to main content

BioCryst Pharmaceuticals, Inc.

corporate_fare Company Profile

BioCryst Pharmaceuticals, Inc.

BCRX·NASDAQ·Life Sciences·CIK 0000882796

We are a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema ("HAE") and other rare diseases. The company has a commercial infrastructure for ORLADEYO, an oral, once-daily therapy for the prevention of HAE attacks, which was discovered and developed internally. This commercial platform is leveraged to commercialize a pipeline of potential first-in-class or best-in-class oral small molecule and injectable protein therapeutics for rare diseases, pursued through internal discovery and strategic business development. The company's commercially available or actively developed molecules include: - ORLADEYO® (berotralstat), an Oral Serine Protease Inhibitor Targeting Kallikrein, approved in the United States and multiple global markets as a once-daily oral capsule treatment for Hereditary Angioedema. A once-daily oral pellets treatment for patients 2 to <12 years of age is approved in the United States for Hereditary Angioedema. - Navenibart (STAR-0215), a Monoclonal Antibody Plasma Kallikrein Inhibitor, in Phase 3 for Hereditary Angioedema. - BCX17725, a Protein Therapeutic, in Phase 1 for Netherton Syndrome. - Avoralstat, an Ocular Plasma Kallikrein Inhibitor, in Phase 1 for Diabetic Macular Edema. - STAR-0310, a Monoclonal Antibody OX40 Antagonist, in Phase 1a for Atopic Dermatitis. - RAPIVAB® (peramivir injection), an Intravenous Neuraminidase Inhibitor, approved in the United States, Australia & Canada for Acute Uncomplicated Influenza. - RAPIACTA® (peramivir injection), an Intravenous Neuraminidase Inhibitor, for Uncomplicated... (text truncated). The company is also pursuing certain pre-clinical medicines for other rare disease targets.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 20 items for BCRX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for BCRX spans 10-Q, 8-K, 8-K/A, 10-K.

Recent high-impact activity:

  • BioCryst 10-Q Details Q3 Profit, $375M Liquidity and Specialty Pharmacy Inventory Boost
  • BioCryst Q3 Revenue $180.3M, Net Income $37.9M; Raises Total Revenue Guidance
  • BioCryst Swings to $37.9M Third-Quarter Profit
  • FDA Approves ORLADEYO Oral Pellets for Adults and Teens With HAE
  • Japan Approves ORLADEYO for Pediatric HAE, Expanding Market

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$874.84M
Net Income
$263.86M
Diluted EPS
$1.21
Op. Cash Flow
$347.37M
Free Cash Flow
$344.9M
Gross Profit
$855.76M
Operating Income
$340.99M
Cash & Equivalents
$89.74M
Total Debt
$0
Debt / Equity
0.00×
Net Margin
30.2%
Shares Outstanding
213.06M sh
Source: 10-K · filed 2026-02-26 · accession 0001628280-26-012240

Short Interest & Short Volume

5.09 days to cover

FINRA reported short interest of 27,637,852 shares in BCRX as of the October 30, 2026 settlement, a 3.9% increase from the prior period — about 5.1 days to cover at its recent average daily volume. On November 20, 2026, 47.9% of BCRX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)27,637,852 shares as of October 30, 2026
Change vs prior period▲ 3.9%
Days to cover5.09 at avg daily volume of 5,429,684
Daily short volume (FINRA facilities)47.9% of 1,340,748 shares on November 20, 2026
5-day average short volume49.0%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with B →
$7.1 -1.66% today
52-week range · as of 2026-11-04 $6.23 – $11.22
Market cap
$1.86B
Volume
3.8M (0.7× avg)
3-mo avg 5.2M
Live data · 2026-11-21 15:55 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed BCRX - Latest Insights

BCRX
Nov 04, 2026, 4:04 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $8.24
Real-time Price: $7.10 info
Change: -$1.14 (-14%) info
Market Cap: $1.858B info
BCRX
Nov 04, 2026, 7:03 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.66
Real-time Price: $7.10 info
Change: -$1.56 (-18%) info
Market Cap: $1.858B info
BCRX
Nov 04, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $8.52
Real-time Price: $7.10 info
Change: -$1.42 (-17%) info
Market Cap: $1.858B info
BCRX
Oct 21, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $8.02
Real-time Price: $7.10 info
Change: -$0.9185 (-11%) info
Market Cap: $1.858B info
BCRX
Aug 25, 2026, 7:01 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $9.65
Real-time Price: $7.10 info
Change: -$2.55 (-26%) info
Market Cap: $1.858B info
BCRX
Aug 05, 2026, 7:02 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $9.65
Real-time Price: $7.10 info
Change: -$2.55 (-26%) info
Market Cap: $1.858B info
BCRX
Aug 04, 2026, 7:01 AM EDT
Filing Type: 8-K/A
Importance Score:
7
Price at Filing: $8.89
Real-time Price: $7.10 info
Change: -$1.79 (-20%) info
Market Cap: $1.858B info
BCRX
Jun 29, 2026, 7:06 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $9.43
Real-time Price: $7.10 info
Change: -$2.33 (-25%) info
Market Cap: $1.858B info
BCRX
Jun 29, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $9.49
Real-time Price: $7.10 info
Change: -$2.39 (-25%) info
Market Cap: $1.858B info
BCRX
Jun 12, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.70
Real-time Price: $7.10 info
Change: -$1.60 (-18%) info
Market Cap: $1.858B info
BCRX
May 06, 2026, 4:06 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $8.77
Real-time Price: $7.10 info
Change: -$1.67 (-19%) info
Market Cap: $1.858B info
BCRX
May 06, 2026, 7:08 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $9.00
Real-time Price: $7.10 info
Change: -$1.90 (-21%) info
Market Cap: $1.858B info
BCRX
May 06, 2026, 7:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $9.49
Real-time Price: $7.10 info
Change: -$2.39 (-25%) info
Market Cap: $1.858B info
BCRX
May 04, 2026, 7:06 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $9.28
Real-time Price: $7.10 info
Change: -$2.18 (-23%) info
Market Cap: $1.858B info
BCRX
May 04, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $9.28
Real-time Price: $7.10 info
Change: -$2.18 (-23%) info
Market Cap: $1.858B info
BCRX
Feb 26, 2026, 4:03 PM EST
Filing Type: 10-K
Importance Score:
9
Price at Filing: $7.90
Real-time Price: $7.10 info
Change: -$0.800 (-10%) info
Market Cap: $1.858B info
BCRX
Feb 26, 2026, 7:19 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $7.83
Real-time Price: $7.10 info
Change: -$0.730 (-9%) info
Market Cap: $1.858B info
BCRX
Jan 23, 2026, 4:30 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $6.70
Real-time Price: $7.10 info
Change: +$0.400 (+6%) info
Market Cap: $1.858B info
BCRX
Jan 12, 2026, 4:28 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.23
Real-time Price: $7.10 info
Change: -$0.130 (-2%) info
Market Cap: $1.858B info
BCRX
Jan 09, 2026, 7:01 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $7.62
Real-time Price: $7.10 info
Change: -$0.520 (-7%) info
Market Cap: $1.858B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets